Le Lézard
Classified in: Health, Science and technology
Subject: PER

EverGlade Consulting Welcomes New Managing Director, Joe Larsen


By Madison Fichtner, Operations Manager

HOUSTON, May 1, 2024 /PRNewswire/ -- EverGlade Consulting is pleased to announce the appointment of Dr. Joe Larsen as Managing Director, effective April 2024. Dr. Larsen brings with him a rich background in biomedical research and healthcare policy, significantly enhancing EverGlade's capabilities in navigating complex regulatory and scientific challenges. His impressive career spans over two decades, during which he has held pivotal roles in both governmental and private sectors.

Prior to joining EverGlade, Dr. Larsen spent five years at biotechnology companies developing anti-infective drugs for the treatment of antibiotic resistant bacteria. He served as the Vice President of Clinical Development at Locus Biosciences, where he led the development of novel bacteriophage therapies. Before that, he served as Vice President, Strategic Portfolio Development at Venatorx Pharmaceuticals, where he managed the biodefense development program for two antibiotic candidates.

"I look forward to providing strategic leadership within Everglade to ensure we remain committed to providing high quality technical, financial, and program management services for our clients and delivering the value they expect." ? Dr. Joe Larsen Ph.D, Managing Director

Dr. Larsen's extensive government service includes significant roles at the Biomedical Advanced Research and Development Authority (BARDA), where he served as Deputy Director of the Division of CBRN Medical Countermeasures. In that role, Dr. Larsen helped lead the strategic planning and execution of BARDA's advanced research and development funding as well as Project Bioshield. Joe also initiated BARDA's Antimicrobial Program and led the establishment of CARB-X, a global accelerator for novel preclinical antimicrobial vaccines, diagnostics, and therapies. His work focused on developing strategies to prepare for and respond to mass public health emergencies involving chemical, biological, radiological, and nuclear threats, a testament to his commitment to public health and safety.

Dr. Larsen holds a Ph.D. in Microbiology and Immunology from the Uniformed Services University of the Health Sciences and a Bachelor of Arts from the University of Kansas.

"I am thrilled to welcome Joe to the team, and know he will be able to enhance the expertise available to our clients." ? Eric Jia-Sobota, Founder and National Consulting Leader

Dr. Larsen's addition to the EverGlade team underscores the firm's commitment to leadership excellence and its dedication to providing cutting-edge solutions in healthcare consulting. His expertise will be instrumental in guiding EverGlade through its next phase of growth and innovation.

About EverGlade Consulting:

EverGlade Consulting is a national consulting firm connecting public sector needs with private sector solutions. We offer services ranging from Pursuit, Proposal and Post-Award support to comply with federal regulations at agencies including BARDA, ASPR, NIH, DTRA, JPEO, DOD, DIU, DOE, and DARPA. 

For additional information about EverGlade Consulting, reach out to:

[email protected] 

SOURCE EverGlade Consulting


These press releases may also interest you

at 07:00
In recognition of Clinical Trials Day, The Trial for #ClinicalEquality ?a longstanding and widely celebrated initiative from FCB Health New York, an IPG Health company ? continues the fight to increase equity in clinical trials with the next phase of...

at 06:52
According to the latest BCC Research study, the demand for the Global Prenatal Testing Market is expected to grow from $10.9 billion in 2023 and is projected to reach $19.8 billion by the end of 2028, at a compound annual growth rate (CAGR) of 12.6%...

at 06:32
"According to the latest BCC Research study, the demand for Medical Robotics and Computer-assisted Surgery: The Global Market is expected to grow from $11.5 billion in 2023 and is projected to reach $19.5 billion by the end of 2028, at a compound...

at 06:15
The Barbara Ann Karmanos Cancer Institute welcomes Wasif Saif, M.D., MBBS, as the new leader of the Phase 1 Clinical Trials Multidisciplinary Team and co-leader of the Gastrointestinal (GI) and Neuroendocrine Oncology Multidisciplinary Team...

at 06:07
Seed Health will present new clinical data on its flagship innovation, DS-01® Daily Synbiotic, a 24-strain probiotic and prebiotic, at the upcoming 2024 Digestive Disease Week® (DDW) meeting. The presentations will highlight the results from two...

at 06:05
Arrowhead Pharmaceuticals, Inc. today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS)...



News published on and distributed by: